Why Generic EpiPen Is Not The Answer – Until FDA Says It Is
Executive Summary
There is no question that the concerns over Mylan’s price increases for EpiPen would deflate as rapidly as the price once an interchangeable generic is approved by FDA, but putting pressure on FDA to get a generic to market may be counterproductive.
You may also be interested in...
Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore
The latest drug development news and highlights from our FDA Performance Tracker.
Gottlieb Joins HHS Transition Team; Will Next Stop Be FDA?
Former US FDA, CMS official has been among those thought to be in the running for Trump's FDA commissioner nomination.
A Tale Of Two Committees: Which Probed EpiPen Better?
If you were an FDA official, would you prefer to be a sideshow at a contentious House committee hearing or the focus of a cordial Senate one?